Quantcast
Home > Quotes > AFMD

Affimed N.V. (AFMD) Quote & Summary Data

AFMD 
$2.9
*  
0.04
1.36%
Get AFMD Alerts
*Delayed - data as of Jan. 24, 2020  -  Find a broker to begin trading AFMD now
Exchange:NASDAQ
Industry: Health Care
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.05 / $ 2.86
Share Volume
661,018
50 Day Avg. Daily Volume
912,378
Previous Close
$ 2.94
52 Week High / Low
$ 4.68 / $ 2.18
Market Cap
221,060,968
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
661,018
50 Day Avg. Daily Volume:
912,378

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.15

Trading Range

The current last sale of $2.90 is 33.03% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.05 $ 4.68
 Low: $ 2.86 $ 2.18

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (Natural Killer cells, or NK cells and macrophages), and T cells. Leveraging our fit-for-purpose ROCKĀ® (Redirected Optimized Cell Killing) platform, we develop proprietary, next-generation bispecific antibodies, so-called immune cell engagers, which are designed to direct and establish a bridge between either innate immune cells or T cells and cancer cells. Our immune cell engagers have the ability to bring innate immune cells or T cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells.  ... More ...  



Risk Grade

Where does AFMD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.01
Open Date:
Jan. 24, 2020
Close Price:
$ 2.90
Close Date:
Jan. 24, 2020


Consensus Recommendation

Analyst Info